English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Financial Funds & Equities
笃定前行 进军千亿 禹洲地产(01628.HK)持续兑现稳增长 高盈利 控负债
Apr 01, 2020 16:24 HKT
篤定前行 進軍千億 禹洲地產(01628.HK)持續兌現穩增長 高盈利 控負債
Apr 01, 2020 16:22 HKT
Shenwan Hongyuan Announces 2019 Annual Results
Mar 28, 2020 19:57 HKT
China Southern Selected Growth Balanced Fund Wins Morningstar Balanced Fund Award
Mar 28, 2020 12:30 HKT
AIM ImmunoTech(AIM)宣布进一步加大临床试验力度,评估安普利近作为当前新冠肺炎流行病的潜在保护性和早期疗法的疗效
Mar 26, 2020 20:00 HKT
AIM ImmunoTech(AIM)宣布進一步加大臨床試驗力度,評估安普利近作為當前新冠肺炎流行病的潛在保護性和早期療法的療效
Mar 26, 2020 20:00 HKT
Yamada Consulting and ZICO Unveil Advisory and Consulting Services Platform to Bridge Urgent Funding Gap Between Japan and ASEAN SMEs
Mar 26, 2020 11:00 HKT
德视佳2019年全年收入增长14% 2020年将推出新的诊所和服务助未来的增长
Mar 26, 2020 09:02 HKT
德視佳2019年全年收入增長14% 2020年將推出新的診所和服務助未來的增長
Mar 26, 2020 09:01 HKT
EuroEyes's Revenue in 2019 Rose by 14%, Launch New Clinics and Services in 2020 to Boost Future Growth
Mar 26, 2020 09:00 HKT
Greenbriar Capital Corp. to Participate in Grit Capital's #ESG Investor Webcast Live on March 25th, 2020
Mar 23, 2020 15:00 HKT
新战略指引新方向,光大控股公布2019年全年业绩
Mar 19, 2020 20:32 HKT
新戰略指引新方向,光大控股公佈2019年全年業績
Mar 19, 2020 20:31 HKT
HKTDC Export Index 1Q20: Exporter confidence hits record low amid COVID-19 outbreak
Mar 17, 2020 18:00 HKT
Tiger Trade, the one-stop global trading app, launches in Singapore
Mar 13, 2020 16:30 HKT
Leading the Industry in Germany for Years, EuroEyes to Provide China with Vision-Correcting Power
Mar 10, 2020 20:11 HKT
眼科界奥斯卡「蔡司奖」今日揭晓,德视佳(1846.HK)不负众望实现五连冠
Mar 10, 2020 18:47 HKT
眼科界奧斯卡「蔡司獎」今日揭曉,德視佳(1846.HK)不負眾望實現五連冠
Mar 10, 2020 18:45 HKT
AIM ImmunoTech公司的药物安普利近即将接受日本国立传染病研究所的测试,作为引发人类新发传染病——新型冠状病毒肺炎(COVID-19)的新型SARS冠状病毒(SARS-CoV-2)潜在治疗药物
Mar 10, 2020 10:00 HKT
AIM ImmunoTech公司的藥物安普利近即將接受日本國立傳染病研究所的測試,作為引發人類新發傳染病——新型冠狀病毒肺炎(COVID-19)的新型SARS冠狀病毒(SARS-CoV-2)潛在治療藥物
Mar 10, 2020 10:00 HKT
<< Previous  Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: